Clinipace CE Jeff Williams Selected to PharmaVoice 100
The News Review:
- Clinipace CE Jeff Williams Selected to PharmaVoice 100
- Party drugs helping spread HIV
- PRA International in 790 mln usd merger agreement with Genstar Capital
Clinipace CE Jeff Williams Selected to PharmaVoice 100
carolinanewswire.com – Jul 25, 2007
Clinipace’s Jeff Williams was appropriately positioned in “The Risk Takers” category. As defined by PharmaVICE these entrepreneurs are redefining the life-sciences industry through innovative approaches to improving technologies processes services and ultimately patient care. About Clinipace Clinipace is a clinical research software company providing a single integrated data capture and study management platform for post-approval research and registries conducted by biopharmaceutical and medical device companies Clinical Research rganizations (CRs) and Academic Medical Centers (AMCs). ur platform called Tempo is delivered via a web-based on-demand architecture that streamlines the clinical research process by eliminating the integration headaches associated with multiple platforms reducing project efforts and costs from startup to conclusion and empowering project stakeholders to make informed real-time decisions regarding their research. For more information on Clinipace please visit:.
Party drugs helping spread HIV
The Australian – Jul 25, 2007
He suggested that the drugs reduced inhibitions making it more likely that users engaged in unsafe sex. Although the trend is alarming and has been observed in several countries including the US and Canada HIV-AIDS expert John Kaldor said the local situation was different. "So far methamphetamine use is not associated with HIV infection in a serious way in Australia" said Professor Kaldor deputy director of the National Centre in HIV Epidemiology and Clinical Research and co-chairman of the local arm of the conference. "The extent of methamphetamine (use) is still low in our population. But it is something we keep a close eye on here. " In response to the findings the AIDS Council of NSW called for increased funding for drug and alcohol research. "The relationship between crystal use and potential HIV transmission is a complex one said Stevie Clayton head of ACN.
PRA International in 790 mln usd merger agreement with Genstar Capital
Forbes – Jul 25, 2007
8 pct of the outstanding PRA shares. The transaction is valued at approximately 790 mln usd. Under the terms of the agreement PRA stockholders will receive 30. 50 usd in cash for each share of PRA common stock representing a premium of approximately 13 pct to PRA’s closing share price on July 24 and a premium of approximately 24 pct to PRA’s average closing share price for the three months ended July 24.
Written by admin on July 25th, 2007 with
no comments.
Read more articles on News.